Article

Loss of SOCS3 in T helper cells resulted in reduced immune responses and hyperproduction of interleukin 10 and transforming growth factor–β1

Division of Molecular and Cellular Immunology, Medical Institute of Bioregulation, Kyushu University, Higashi-ku, Fukuoka 812-8582, Japan.
Journal of Experimental Medicine (Impact Factor: 13.91). 05/2006; 203(4):1021-31. DOI: 10.1084/jem.20052333
Source: PubMed

ABSTRACT Suppressor of cytokine signaling (SOCS)3 is a major negative feedback regulator of signal transducer and activator of transcription (STAT)3-activating cytokines. Transgenic mouse studies indicate that high levels of SOCS3 in T cells result in type 2 T helper cell (Th2) skewing and lead to hypersensitivity to allergic diseases. To define the physiological roles of SOCS3 in T cells, we generated T cell-specific SOCS3 conditional knockout mice. We found that the mice lacking SOCS3 in T cells showed reduced immune responses not only to ovalbumin-induced airway hyperresponsiveness but also to Leishmania major infection. In vitro, SOCS3-deficient CD4+ T cells produced more transforming growth factor (TGF)-beta1 and interleukin (IL)-10, but less IL-4 than control T cells, suggesting preferential Th3-like differentiation. We found that STAT3 positively regulates TGF-beta1 promoter activity depending on the potential STAT3 binding sites. Furthermore, chromatin immunoprecipitation assay revealed that more STAT3 was recruited to the TGF-beta1 promoter in SOCS3-deficient T cells than in control T cells. The activated STAT3 enhanced TGF-beta1 and IL-10 expression in T cells, whereas the dominant-negative form of STAT3 suppressed these. From these findings, we propose that SOCS3 regulates the production of the immunoregulatory cytokines TGF-beta1 and IL-10 through modulating STAT3 activation.

1 Follower
 · 
128 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: The role of tumor-induced immune modulation in cancer progression is currently a focus of investigation. The signal transducer and activator of transcription 3 (STAT3) is an established molecular hub of immunosuppression, and its signaling pathways are classically overactivated within malignancies. This article will review STAT3 operational mechanisms within the immune system and the tumor microenvironment, with a focus on therapeutic strategies that may impact outcomes for patients with cancer.
    Journal of Neuro-Oncology 02/2015; DOI:10.1007/s11060-015-1731-3 · 2.79 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: In our review, we address the role of signal transducer and activator of transcription-3 (STAT3) and suppressor of cytokine signaling-3 (SOCS3) in the outcome of Mycobacterium tuberculosis infection, focusing on functions of these molecules in regulating the biology of myeloid and lymphoid cells. The STAT3 transcription factor has paradoxical roles: mainly activating an anti-inflammatory program in myeloid cells while promoting the differentiation and activation of inflammatory T cells. STAT3 is a major player in all phases of T cell responses, including T cell subset differentiation, T cell activation, and generation of memory. We review the roles of cytokines that activate, or are activated by, STAT3 during the infection with M. tuberculosis. SOCS3 inhibits STAT3 activation, by some but not all STAT3-activating cytokine receptors. Infection with M. tuberculosis also stimulates SOCS3 expression in phagocytes. Studies in different mouse models have proven the critical importance of SOCS3 in restraining inflammation and allowing optimal levels of protective immune responses against the infection. The accumulated data presented here suggest a relevant program coordinated by SOCS3 in different cell populations, which results in improved control of infection with M. tuberculosis. STAT3 and SOCS3 may thus be targeted to improve the control of infection with M. tuberculosis or the efficiency of vaccination.
    Seminars in Immunology 11/2014; 26(6). DOI:10.1016/j.smim.2014.10.004 · 6.12 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Mesenchymal stem cells (MSCs) are immunoregulatory, and the administration of them has been shown to ameliorate inflammation caused by Th17 cells. However, the mechanisms that contribute to MSC regulation on Th17 cell development are unclear. Here, we found that MSCs could inhibit Th17 cell differentiation through the activation of suppressors of cytokine signaling 3 (SOCS3) when coculture of MSCs and CD4(+)CD25(low)CD44(low)CD62L(high) T cells. Further analysis demonstrated that the inhibitory action was mediated via interferon gamma (IFN-γ), which activated signal transducer and activator of transcription-1 (STAT1) to enhance the expression of SOCS3, leading to STAT3 inhibition. Moreover, stable and reciprocal changes in H3K4me3 and H3K27me3 at the promoters of STAT1, STAT3 and RORγt determined the fate of Th17 cells. These results demonstrate that MSCs may inhibit Th17 differentiation via IFN-γ that activates SOCS3 leading to immunomodulatory effects, suggesting a possible mechanism by which MSCs could act as a cellular approach to attenuate the clinical and pathological manifestations of some autoimmune diseases.
    Immunologic Research 01/2015; 61(3). DOI:10.1007/s12026-014-8612-2 · 3.53 Impact Factor

Full-text (5 Sources)

Download
103 Downloads
Available from
May 26, 2014